BioTime CEO Explains What Could Happen To Stem Cell Research And The Company Under A New Guard In Washington

By: via Benzinga
BioTime, Inc. (NYSE: BTX) is a clinical-stage biotechnology company working on regenerative medicine and pluripotent stem cell ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.